Julius Knowles, Director at Keros Therapeutics, Inc. (KROS), sold 24,339 shares at $40.16 ($976K) on 2021-10-01, disclosed to the SEC on 2021-10-05.
Open-market sale of $976k KROS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $40.16 | 2,496 | $100K | 10.3% |
| 2 | $40.16 | 2,496 | $100K | 10.3% |
| 3 | $40.16 | 3,827 | $154K | 15.7% |
| 4 | $40.16 | 3,827 | $154K | 15.7% |
| 5 | $40.06 | 1,479 | $59K | 6.1% |
| 6 | $40.06 | 1,479 |
| $59K |
| 6.1% |
| 7 | $40.06 | 2,267 | $91K | 9.3% |
| 8 | $40.06 | 2,267 | $91K | 9.3% |
| 9 | $40.03 | 1,033 | $41K | 4.2% |
| 10 | $40.03 | 1,584 | $63K | 6.5% |
| 11 | $40.03 | 1,584 | $63K | 6.5% |
| Total | $40.11 avg | 24,339 | $976K | 100% |
| Filing → |
| KROS | SELL | 2022-01-05 | $5.3M | — | Filing → |
| KROS | SELL | 2021-12-03 | $5.1M | — | Filing → |
| KROS | SELL | 2021-11-03 | $3.9M | — | Filing → |